In order to highlight the priorities of the sector when there are just over seven months left for the next European elections, a manifesto, made public by the European Federation of the Pharmaceutical Industry (EFPIA), in which Farmaindustria is integrated, has collected as requests from the pharmaceutical industry to the future Europe to recognize the value of innovation through the measurement of health outcomes, maintain the strength of the current European model for the protection of intellectual and industrial property and turn Europe into a world power in clinical research through a framework that favors the development of clinical trials and public-private collaboration.
The document is based on three main concepts: ‘Health for all’, ‘European excellence’ and ‘Together we are stronger’. In the first case, the manifesto highlights how, thanks in large part to biomedical R & D led by the pharmaceutical industry in collaboration with health systems, and also to advances in prevention, diagnosis and treatment, large advances in the last decades in the fight against diseases, which means that the citizens of the European Union (EU) today live 30 years more than a century ago.
The document also defends the validity of vaccines as “the most effective method to prevent communicable diseases” and endorses the warnings of the World Health Organization (WHO) that the reluctance to vaccination is “a problem global complex that requires continuous monitoring “.
The second major objective of the manifesto is to join forces to try to position the EU as a “world leader in biomedical R & D”, on the basis that Europe is the second largest pharmaceutical market on a global scale, accounting for 22 percent of all sales of medicines, although “industrial and R & D investments are diverting from Europe to other more attractive places”.
Faced with this reality, the signers of the document are committed to “keeping Europe at the forefront of medical innovation”, a field, that of R & D, in which the sector employs 115,000 people. For this, it indicates that it is necessary “to improve the position of Europe in the rapidity of the processing of innovative therapies that cover unmet health needs”, ensuring that the European Medicines Agency (EMA) has the flexibility and resources necessary to continue at the forefront of global regulatory excellence.
On the other hand, the pharmaceutical industry believes that the time has come to “move forward on a smart European agenda to promote investment and actively use Europe’s trade policy to promote European regulatory and industrial protection frameworks, as well as its approach to resistance antimicrobial “.
The third pillar of this manifesto is the promotion of public-private collaboration, which as reflected “is already achieving excellent results” in research through cooperation between public authorities, regulatory bodies, universities, hospitals, centers of research, patient associations and industry.
Farmaindustria notes that “this is essential to position Europe as the world’s leading center for clinical trials, as shown by projects such as the European Initiative for Innovative Medicines (IMI), the largest public-private health alliance in the world, with a total budget. of 5,000 million euros, half of which are provided by the European Commission and the other half by the pharmaceutical industry. ”
Distefar supports this type of requests whose aim is to turn Europe into a world power in clinical research.